Calamos Advisors’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.51M Hold
35,527
0.02% 502
2025
Q4
$6.25M Sell
35,527
-1,443
-4% -$236K 0.02% 494
2025
Q3
$5.18M Hold
36,970
0.02% 536
2025
Q2
$4.64M Hold
36,970
0.02% 557
2025
Q1
$5.06M Buy
36,970
+412
+1% +$58.9K 0.02% 522
2024
Q4
$5.59M Hold
36,558
0.02% 505
2024
Q3
$7.09M Sell
36,558
-897
-2% -$188K 0.03% 481
2024
Q2
$8.68M Sell
37,455
-1,367
-4% -$297K 0.04% 435
2024
Q1
$8.37M Sell
38,822
-976
-2% -$229K 0.04% 438
2023
Q4
$10.3M Sell
39,798
-520
-1% -$128K 0.05% 383
2023
Q3
$10.4M Hold
40,318
0.05% 385
2023
Q2
$11.5M Hold
40,318
0.06% 380
2023
Q1
$11.2M Sell
40,318
-5,041
-11% -$1.39M 0.05% 402
2022
Q4
$12.6M Sell
45,359
-8,020
-15% -$2.27M 0.06% 398
2022
Q3
$14.3M Hold
53,379
0.07% 346
2022
Q2
$10.9M Buy
53,379
+1,438
+3% +$294K 0.05% 458
2022
Q1
$10.9M Buy
51,941
+6,923
+15% +$1.51M 0.04% 493
2021
Q4
$10.8M Buy
45,018
+1,743
+4% +$448K 0.04% 464
2021
Q3
$12.2M Buy
43,275
+3,818
+10% +$1.25M 0.05% 368
2021
Q2
$13.7M Buy
39,457
+6,547
+20% +$1.98M 0.06% 323
2021
Q1
$9.21M Buy
32,910
+958
+3% +$258K 0.05% 358
2020
Q4
$7.82M Sell
31,952
-1,341
-4% -$346K 0.05% 383
2020
Q3
$9.45M Sell
33,293
-2,752
-8% -$768K 0.06% 315
2020
Q2
$9.64M Sell
36,045
-2,183
-6% -$656K 0.07% 298
2020
Q1
$12.1M Sell
38,228
-3,089
-7% -$937K 0.09% 239
2019
Q4
$12.3M Sell
41,317
-1,192
-3% -$331K 0.06% 307
2019
Q3
$9.9M Buy
42,509
+3,447
+9% +$803K 0.05% 341
2019
Q2
$9.13M Sell
39,062
-33,902
-46% -$7.83M 0.05% 359
2019
Q1
$17.2M Sell
72,964
-19,664
-21% -$6.19M 0.11% 244
2018
Q4
$27.9M Buy
92,628
+26,572
+40% +$8.48M 0.18% 165
2018
Q3
$23.3M Buy
66,056
+32,896
+99% +$11.3M 0.13% 202
2018
Q2
$9.62M Buy
33,160
+2,002
+6% +$563K 0.06% 328
2018
Q1
$8.53M Buy
31,158
+1,358
+5% +$422K 0.06% 338
2017
Q4
$9.49M Sell
29,800
-550
-2% -$176K 0.05% 303
2017
Q3
$9.5M Buy
30,350
+1,545
+5% +$457K 0.07% 286
2017
Q2
$7.82M Buy
28,805
+713
+3% +$189K 0.06% 318
2017
Q1
$7.68M Sell
28,092
-60
-0.2% -$17K 0.06% 311
2016
Q4
$7.98M Sell
28,152
-36,663
-57% -$10.9M 0.06% 290
2016
Q3
$20.3M Sell
64,815
-93
-0.1% -$27.5K 0.15% 190
2016
Q2
$15.7M Sell
64,908
-18
-0% -$4.74K 0.11% 220
2016
Q1
$16.9M Buy
64,926
+1,881
+3% +$497K 0.11% 206
2015
Q4
$19.3M Sell
63,045
-33,891
-35% -$9.74M 0.12% 199
2015
Q3
$28.3M Sell
96,936
-213,047
-69% -$70.4M 0.19% 165
2015
Q2
$125M Buy
309,983
+100,287
+48% +$40.2M 0.77% 22
2015
Q1
$88.5M Buy
209,696
+54,657
+35% +$21.5M 0.56% 46
2014
Q4
$52.6M Sell
155,039
-1,647
-1% -$533K 0.35% 83
2014
Q3
$51.8M Sell
156,686
-25,893
-14% -$8.54M 0.35% 84
2014
Q2
$57.6M Sell
182,579
-18,118
-9% -$5.45M 0.36% 78
2014
Q1
$61.4M Buy
200,697
+34,466
+21% +$10.9M 0.39% 71
2013
Q4
$46.5M Sell
166,231
-21,899
-12% -$5.66M 0.3% 92
2013
Q3
$45.3M Buy
188,130
+15,651
+9% +$3.5M 0.28% 96
2013
Q2
$37.1M Buy
+172,479
New +$36.9M 0.24% 112

Other funds holding BIIB

Calamos Advisors's BIIB Position: Q1 2026 in Review

Calamos Advisors held its Biogen (BIIB) position steady in Q1 2026 at 35,527 shares worth $6.51M. The position accounts for 0.02% of the portfolio, ranked #502.

Calamos Advisors first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $125M in Q2 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Calamos Advisors held 35,527 shares of Biogen worth $6.51M as of Q1 2026.
  • Calamos Advisors left its Biogen share count unchanged in Q1 2026.
  • Biogen made up 0.02% of Calamos Advisors's portfolio in Q1 2026, its #502 holding.
  • Calamos Advisors first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
  • Calamos Advisors's Biogen position peaked at $125M in Q2 2015.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.